Expanding its global brand presence in the needle-free segment, backed by distribution agreements in 44 countries
Special terms and training support for domestic medical institutions newly adopting the device in Q4

Promotional image celebrating the shipment of 1,000 CureJet units / Photo provided by Vaz Biomedic

Promotional image celebrating the shipment of 1,000 CureJet units / Photo provided by Vaz Biomedic

View original image

Buzz Biomedic said it is holding a special promotion for domestic medical institutions newly adopting its needle-free device, Curejet (CUREjet), from October 1 through December 31, 2026, to mark global shipments reaching 1,000 units.


Curejet is a medical needle-free drug delivery device that delivers medication into the dermal layer of the skin using a high-speed microjet of liquid generated by electromagnetic actuation, without the use of needles. The device allows users to adjust injection depth and volume. In medical settings, it is primarily used for intradermal injections for cosmetic skin treatments, such as skin boosters, and for scar treatment.


Curejet is currently supplied to overseas markets under distribution agreements covering 44 countries. The company said it is expanding the brand's presence in the needle-free segment based on this distribution network. Buzz Biomedic views the milestone of 1,000 global shipments as a stepping stone for Curejet to become a "global standard" and has organized the promotion for domestic medical institutions to mark the achievement.


Curejet's surpassing 1,000 global shipments shows that needle-free devices have moved beyond a passing trend in the medical device market and established themselves as a distinct treatment category.


According to the company, domestic medical institutions newly adopting the device and signing a contract during the promotion period will receive special adoption terms. Specific transaction terms, including device configuration and pricing, will be provided in individual quotations and contracts for each institution.


Support will also be provided to help institutions put the device to use after adoption. Medical institutions considering adoption can see the device firsthand through an on-site demonstration. Institutions that adopt it will receive device-use training for medical staff and consultation training for employees. Details of the training, the scope of support, and the schedule can be confirmed for each institution during adoption consultations.


Eligibility for the promotion and the specific terms of application can be confirmed before signing a contract. For inquiries, contact a domestic sales representative at Buzz Biomedic.



Meanwhile, Buzz Biomedic will also participate in major domestic aesthetic medicine conferences held during the promotion period. The company plans to introduce Curejet to Korean medical professionals at the fall academic conference of ASLS Korea (Korean Society for Aesthetic and Laser Medicine), taking place November 7-8, and at the fall academic conference of the Korean Society of Clinical Aesthetic Medicine, taking place November 15.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing